Stack

Cagrilintide

Peptide reference entry

What it is: Amylin analog peptide
What it does: Supports satiety and appetite reduction
Status: Investigational
Evidence: Moderate. Human obesity trials underway.
Uses: Obesity research

Caution. Still in development and not broadly approved.

Summary

Cagrilintide is a long-acting amylin receptor agonist that reduces appetite and slows gastric emptying, often studied in combination with GLP-1 agonists for obesity. Early trials show additive weight loss versus GLP-1 alone, with a generally manageable GI tolerability profile. It remains investigational for chronic weight management and is not yet broadly approved.

Checked Jul 15, 2026.

Keep a record of Cagrilintide in Stack

Stack logs each dose you take, tracks what is left in the vial or bottle and shows how you kept to your plan. It records what you choose and does not recommend anything. Everything stays on your phone, with no account.

Get Stack on Google Play Peptide reconstitution calculator

More peptides

KisspeptinInvestigational · moderate evidence EpithalonExperimental · low evidence EloralintideInvestigational · moderate evidence SemaglutideApproved · high evidence TirzepatideApproved · high evidence

This entry summarises published information in plain language. It is not medical advice, a dosing recommendation or a substitute for a qualified healthcare professional. Many peptides are not approved for human use, and legal status varies by country. Check anything you rely on against primary sources.